Clinical trials: Cardiovascular Disease and Lipoprotein(a)
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis, Cardiovascular Diseases
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- Trial name
- ACCLAIM-CTA (NCT07613294)
- Testing
- Lepodisiran
- Where
- 58 sites in United States, Australia and 5 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Disease and Lipoprotein(a)
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
- Trial name
- Lp(a)HORIZON (NCT04023552)
- Testing
- TQJ230
- Where
- 902 sites in United States, Argentina and 41 more
- Volunteers
- 8,323 people
- Sponsor
- Novartis Pharmaceuticals
Lipoprotein Disorder
A Study of DII235 in Adults With Elevated Lipoprotein(a)
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
- Trial name
- NCT07235046
- Testing
- DII235, Saline
- Where
- 63 sites in United States, China and 2 more
- Volunteers
- 234 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Elevated Lipoprotein(a) in Hospital Staff
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.
- Conditions
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
- Trial name
- LPACO (NCT06304415)
- Where
- Singapore
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism
40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month.
- Conditions
- Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility, Low-density Lipoprotein Lipid Composition, Cardiovascular Diseases
- Trial name
- EPA&LDL (NCT04152291)
- Testing
- Ethyl-Eicosapentaenoic Acid (E-EPA)
- Where
- Finland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Wihuri Research Institute
Cardiovascular Diseases, Atherosclerosis
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
- Trial name
- NCT05537571
- Testing
- SLN360
- Where
- 29 sites in Australia, Czechia and 5 more
- Volunteers
- 180 people
- Sponsor
- Silence Therapeutics plc
Lipoprotein Disorder
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- KRAKEN (NCT05563246)
- Testing
- LY3473329
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol…
- Conditions
- Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
- Trial name
- SPIRIT (NCT04807400)
- Testing
- Inclisiran, Behavioural Support, Background lipid lowering therapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 892 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases, Apolipoproteins
Functional Yogurt Consumption and Its Effects on the Lipid Profile of Healthy Subjects
The purpose of this study was to assess the effect of the daily intake of yogurts enhanced with Sacha Inchi oil and hybrid palm tree oil on human plasma lipids related to cardiovascular risk factors
- Conditions
- Cardiovascular Diseases, Apolipoproteins, Food Preferences, Low-density-lipoprotein-type
- Trial name
- FYOPO (NCT06574711)
- Testing
- Sacha inchi oil yogurt, Hybrid palm oil yogurt, Control yogurt
- Where
- Colombia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Javeriana
Cardiovascular Diseases, Cardiovascular Morbidity
Observational Study of Cardiovascular Disease.
This observational study will follow participants who completed follow-up in the FOURIER OUTCOMES trial to evaluate the long-term effects of evolocumab treatment.
- Conditions
- Cardiovascular Diseases, Cardiovascular Morbidity, Coronary Heart Disease, Low-density-lipoprotein-type
- Trial name
- FOURIER LEGACY (NCT04128475)
- Testing
- N/A - observational study.
- Where
- 3 sites in United States, Norway and 1 more
- Volunteers
- 1,137 people
- Sponsor
- University of Sydney
Intra-abdominal Fat, Metabolic Syndrome
Habitual Diet and Avocado Trial
The Habitual Diet and Avocado Trial will evaluate the effects of providing one avocado per day for recommended consumption over a 6 month period in a cohort of approximately 1000 free-living participants with increased waist…
- Conditions
- Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High
- Trial name
- HAT (NCT03528031)
- Testing
- Intervention Daily Avocado
- Where
- 4 sites in United States
- Volunteers
- 1,008 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Acute Coronary Syndrome, Lipoprotein Disorder
Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study
Several clinical and preclinical studies have focused interest on lipoprotein(a) [Lp(a)], showing a direct and independent relationship of its circulating levels with the progression of atherosclerosis and its clinical…
- Conditions
- Acute Coronary Syndrome, Lipoprotein Disorder, Acute Myocardial Infarction, Cardiovascular Diseases
- Trial name
- RELACS (NCT05496790)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- University of Campania Luigi Vanvitelli
Cardiovascular Disease and Lipoprotein(a)
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
- Trial name
- NCT03887520
- Testing
- Blood draw for Lp(a)
- Where
- 900 sites in United States, Argentina and 47 more
- Volunteers
- 49,001 people
- Sponsor
- Novartis Pharmaceuticals
Lipoprotein Metabolism Disorder
Ground Beef and Cardiovascular Disease
This study tested the hypothesis that ground beef high in monounsaturated fat (MUFA) and low in saturated fat (SFA) would increase the high-density lipoprotein-cholesterol concentration and low-density lipoprotein particle…
- Trial name
- NCT04945980
- Testing
- Ground beef
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Elevated Lipoprotein(a), Cardiovascular Disease
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03070782
- Testing
- ISIS 681257
- Where
- 32 sites in United States, Canada and 3 more
- Volunteers
- 286 people
- Sponsor
- Akcea Therapeutics
Lipoprotein Metabolism, PCSK9
Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults
Background: Fish oils are known to be beneficial to health and believed to be cardio-protective. Omega-3 fatty acid is the most known fish oil available in the market.
- Conditions
- Lipoprotein Metabolism, PCSK9, Proteomics
- Trial name
- NCT03043365
- Testing
- control fish oil, LCMUFA-rich saury oil
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel
- Trial name
- NCT03392051
- Testing
- ISIS 681257, Clopidogrel
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.
- Trial name
- NCT03426033
- Testing
- ISIS 681257, Warfarin
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics